Physical and psychological sequelae at three months after acute illness in COVID-19 survivors.


Journal

Panminerva medica
ISSN: 1827-1898
Titre abrégé: Panminerva Med
Pays: Italy
ID NLM: 0421110

Informations de publication

Date de publication:
Sep 2023
Historique:
medline: 27 9 2023
pubmed: 2 6 2021
entrez: 1 6 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) may leave behind an altered health status early after recovery. We evaluated the clinical status of COVID-19 survivors at three months after hospital discharge. In this prospective observational cohort study, hospitalized patients aged ≥18 years, evaluated at one (M1) and three (M3) months post-discharge were enrolled. 251 patients (71.3% males, median [IQR] age 61.8 [53.5-70.7] years) were included. Median (IQR) time from discharge to M3 was 89 (79.5-101) days. Primary outcome was residual respiratory dysfunction (RRD), defined by tachypnea, moderate to very severe dyspnea, or peripheral oxygen saturation ≤95% on room air at M3. RRD was found in 30.4% of patients, with no significant difference compared with M1. Chronic obstructive pulmonary disease and length of stay were independent predictors of RRD at multivariable logistic regression (OR [95% CI]: 4.13 [1.17-16.88], P=0.033; OR [95% CI]: 1.02 [1.00-1.04], P=0.047, respectively). Obesity and C-reactive protein levels upon admission were additional predictors at regression tree analysis. Impaired quality of life (QoL) was reported by 53.2% of patients. Anxiety and insomnia were each present in 25.5% of patients, and PTSD in 22.4%. No difference was found between M1 and M3 in QoL, anxiety or PTSD. Insomnia decreased at M3. Current major psychiatric disorder as well as anxiety, insomnia and PSTD at M1 independently predicted PTSD at M3. Clinical damage may persist at three months after discharge in COVID-19 survivors. Post-recovery follow-up is an essential component of patient management.

Sections du résumé

BACKGROUND BACKGROUND
Coronavirus disease 2019 (COVID-19) may leave behind an altered health status early after recovery. We evaluated the clinical status of COVID-19 survivors at three months after hospital discharge.
METHODS METHODS
In this prospective observational cohort study, hospitalized patients aged ≥18 years, evaluated at one (M1) and three (M3) months post-discharge were enrolled. 251 patients (71.3% males, median [IQR] age 61.8 [53.5-70.7] years) were included. Median (IQR) time from discharge to M3 was 89 (79.5-101) days. Primary outcome was residual respiratory dysfunction (RRD), defined by tachypnea, moderate to very severe dyspnea, or peripheral oxygen saturation ≤95% on room air at M3.
RESULTS RESULTS
RRD was found in 30.4% of patients, with no significant difference compared with M1. Chronic obstructive pulmonary disease and length of stay were independent predictors of RRD at multivariable logistic regression (OR [95% CI]: 4.13 [1.17-16.88], P=0.033; OR [95% CI]: 1.02 [1.00-1.04], P=0.047, respectively). Obesity and C-reactive protein levels upon admission were additional predictors at regression tree analysis. Impaired quality of life (QoL) was reported by 53.2% of patients. Anxiety and insomnia were each present in 25.5% of patients, and PTSD in 22.4%. No difference was found between M1 and M3 in QoL, anxiety or PTSD. Insomnia decreased at M3. Current major psychiatric disorder as well as anxiety, insomnia and PSTD at M1 independently predicted PTSD at M3.
CONCLUSIONS CONCLUSIONS
Clinical damage may persist at three months after discharge in COVID-19 survivors. Post-recovery follow-up is an essential component of patient management.

Identifiants

pubmed: 34060280
pii: S0031-0808.21.04399-8
doi: 10.23736/S0031-0808.21.04399-8
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

312-320

Auteurs

Rebecca DE Lorenzo (R)

Vita-Salute San Raffaele University, Milan, Italy.

Elena Cinel (E)

Vita-Salute San Raffaele University, Milan, Italy.

Marta Cilla (M)

Vita-Salute San Raffaele University, Milan, Italy.

Nicola Compagnone (N)

Vita-Salute San Raffaele University, Milan, Italy.

Marica Ferrante (M)

Vita-Salute San Raffaele University, Milan, Italy.

Elisabetta Falbo (E)

Vita-Salute San Raffaele University, Milan, Italy.

Alessandro Patrizi (A)

Vita-Salute San Raffaele University, Milan, Italy.

Jacopo Castellani (J)

Vita-Salute San Raffaele University, Milan, Italy.

Cristiano Magnaghi (C)

Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Stefania L Calvisi (SL)

Unit of General Medicine and Advanced Care, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Teresa Arcidiacono (T)

Unit of Nephrology, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Chiara Lanzani (C)

Unit of Nephrology, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Valentina Canti (V)

Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Mario G Mazza (MG)

Unit of Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Sabina Martinenghi (S)

Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Giordano Vitali (G)

Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Francesco Benedetti (F)

Unit of Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Fabio Ciceri (F)

Vita-Salute San Raffaele University, Milan, Italy.
Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Caterina Conte (C)

Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Patrizia Rovere Querini (P)

Vita-Salute San Raffaele University, Milan, Italy - rovere.patrizia@hsr.it.
Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Hospital, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH